FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, [	D.C. 20549
---------------	------------

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Graf R. Mark			<u>H</u>	2. Issuer Name and Ticker or Trading Symbol Harmony Biosciences Holdings, Inc. [ HRMY]								lationship of Reporting ck all applicable)  Director  Officer (give title		10% Ov		vner		
(Last)	(Fi	rst)	(Middle)											below)			Other (spector)	becily
C/O HARMONY BIOSCIENCES HOLDINGS, INC.  3. Date of Earliest Transaction (Month 05/20/2021				nth/E	Day/Year)													
630 W. GERMANTOWN PIKE, SUITE 215					A MANAGAMA BANG Girin I Filad (Manh/B. 25.							La tefridades Distractions Effection (Charlet a France)						
(Street)				_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
PLYMOU	· • • • • • • • • • • • • • • • • • • •		19462										)	_	iled by One I iled by More	•	Ü	- 1
MEETIN	G													Persoi		iliali O	пе керог	ung
(City)	(SI	tate) (	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D.				Execution Date,		e, Transaction Disposed Code (Instr. 5)			ities Acqui d Of (D) (Ir	red (A)	4 and Securit Benefic Owned		es F ally ( Following (	6. Owne Form: D D) or In I) (Instr.	irect o direct B	7. Nature of Indirect Beneficial Ownership		
								Code	٧	Amount	(A) or (D)		rice	Transac	Reported Transaction(s) (Instr. 3 and 4)		('	nstr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)  2. Conversio or Exercise Price of Derivative Security			3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		ı of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ov Fo Di or (I)	wnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amo or Num of Sha	nber					
Stock Option	\$32.5	05/20/2021		A		7,246		(1)	05	5/20/2031	Common Stock	7,2	246	\$0.00	7,246		D	

## **Explanation of Responses:**

1. The stock option shall vest in full on the earlier to occur of (i) May 20, 2022 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

## Remarks:

/s/ Christian Ulrich, Attorneyin-fact for R. Mark Graf

06/14/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.